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Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease
Paul Mead, MD1; Jeannine Petersen, PhD1; Alison Hinckley, PhD1
Lyme disease is a tickborne zoonosis for which serologic test-
ing is the principal means of laboratory diagnosis. In 1994, the 
Association of State and Territorial Public Health Laboratory 
Directors, CDC, the Food and Drug Administration (FDA), the 
National Institutes of Health (NIH), the Council of State and 
Territorial Epidemiologists, and the National Committee for 
Clinical Laboratory Standards convened the Second National 
Conference on Serologic Diagnosis of Lyme Disease (1).
The conference proceedings recommended a two-test 
methodology using a sensitive enzyme immunoassay (EIA) or 
immunofluorescence assay as a first test, followed by a western 
immunoblot assay for specimens yielding positive or equivocal 
results (1,2). Regarding the development of future tests, the 
report advised that evaluation of new serologic assays include 
blind testing against a comprehensive challenge panel, and that 
new assays should only be recommended if their specificity, 
sensitivity, and precision equaled or surpassed the performance 
of tests used in the recommended two-test procedure. To assist 
serologic test developers, CDC has made available, with sup-
port from NIH, a comprehensive panel of sera from patients 
with various stages of Lyme disease and other conditions, as 
well as healthy persons (3). 
On July 29, 2019, FDA cleared several Lyme disease serologic 
assays with new indications for use based on a modified two-
test methodology (4). The modified methodology uses a second 
EIA in place of a western immunoblot assay. Clearance by FDA 
of the new Lyme disease assays indicates that test performance 
has been evaluated and is “substantially equivalent to or better 
than” a legally marketed predicate test.
Recommendation
When cleared by FDA for this purpose, serologic assays that 
utilize EIA rather than western immunoblot assay in a two-test 
format are acceptable alternatives for the laboratory diagnosis 
of Lyme disease. Based on the criteria established at the 1994 
Second National Conference on Serologic Diagnosis of Lyme 
Disease, clinicians and laboratories should consider serologic 
tests cleared by FDA as CDC-recommended procedures for 
Lyme disease serodiagnosis. 
Summary
What is already known about this topic?
Serologic testing is the principal means of laboratory diagnosis 
of Lyme disease. Current recommendations include using a 
sensitive enzyme immunoassay (EIA) or immunofluorescence 
assay, followed by a western immunoblot assay for specimens 
yielding positive or equivocal results.
What is added by this report?
On July 29, 2019, the Food and Drug Administration (FDA) 
cleared several Lyme disease serologic assays with new indica-
tions for use, allowing for an EIA rather than western immunoblot 
assay as the second test in a Lyme disease testing algorithm.
What are the indications for public health practice?
When cleared by FDA for this purpose, serologic assays that 
utilize a second EIA in place of western immunoblot assay 
are acceptable alternatives for the serologic diagnosis of 
Lyme disease.
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